Roche's Lung-Cancer Drug Alecensa Gets New FDA Approval
By Adria Calatayud
Roche Holding's Alecensa lung-cancer drug received a new approval from the U.S. Food and Drug Administration as an additional treatment for patients who have undergone surgery to remove their tumor.
The Swiss pharmaceutical giant said Friday that the approval was based on a late-stage trial that showed Alecensa reduced the risk of disease recurrence or death in patients with a type of early-stage resected nonsmall cell lung cancer.
The drug is currently approved in more than 100 countries--including the U.S.--as an initial and second-line treatment for that kind of lung cancer, the company said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
April 19, 2024 01:29 ET (05:29 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
How to Invest Like Warren Buffett
-
Cognizant Earnings: Improved Profitability Buttresses Results as Customer Spending Remains Muted
-
10 Top-Performing Dividend Stocks of the Month